永安药业（002365）(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员会立 案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除留置 通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

Core Viewpoint - The performance of the Zhongzheng 2000 ETF Enhanced (159556) has shown a decline of 2.20% as of the midday close on September 2, with a trading volume of 2.0863 million yuan [1] Group 1: Fund Performance - The Zhongzheng 2000 ETF Enhanced (159556) has a performance benchmark based on the Zhongzheng 2000 Index return [1] - Since its establishment on December 27, 2023, the fund has achieved a return of 18.85% [1] - The fund's return over the past month is reported at 9.45% [1] Group 2: Major Holdings - Major stocks in the fund include: - Zhenhua New Materials, down 1.72% - Hengbao Co., down 8.57% - Yongding Co., down 6.21% - Yong'an Pharmaceutical, down 2.03% - Xuguang Electronics, down 1.07% - Zhongke Technology, down 1.89% - Juguang Technology, down 3.61% - Huitong Energy, down 2.42% - Xinke Materials, down 2.41% - Batian Co., down 3.71% [1]

Group 1 - The graphite electrode sector saw a rise of 2.32%, ranking third among concept sectors, with 12 stocks increasing in value, including Puxin Technology, Shantai Technology, and Suotong Development reaching their daily limit [1][2] - Notable gainers included Zhongke Electric, Bettery, and China Baowu, which rose by 14.59%, 13.58%, and 3.70% respectively [1] - The sector experienced a net outflow of 0.11 billion yuan in main funds, with 8 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan [2][3] Group 2 - The top net inflow was recorded for Suotong Development, with a net inflow of 324 million yuan, followed by Shantai Technology and Puxin Technology with net inflows of 220 million yuan and 205 million yuan respectively [2][3] - The net inflow ratios for Shantai Technology, Suotong Development, and Puxin Technology were 21.42%, 19.39%, and 11.52% respectively [3] - The stocks with the largest declines included Guomin Technology, Yong'an Pharmaceutical, and Huajin Co., which fell by 3.42%, 1.72%, and 1.50% respectively [1][4]

Financial Performance - The company reported a significant decline in net profit, down 76.19% year-on-year, with a total revenue of 367 million yuan, a decrease of 13.72% compared to the previous year [1] - The gross margin fell to 15.81%, a decrease of 40.14%, while the net margin dropped to 2.33%, down 80.6% year-on-year [1] - In the second quarter, total revenue was 196 million yuan, down 14.38%, and net profit was 16.86 million yuan, a decline of 29.16% [1] Key Financial Metrics - The company's operating expenses, including sales, management, and financial costs, totaled 42.14 million yuan, accounting for 11.47% of revenue, an increase of 1.25% year-on-year [1] - Earnings per share decreased to 0.04 yuan, down 75.74% year-on-year, while operating cash flow per share increased by 62.58% to 0.17 yuan [1] - The company’s return on invested capital (ROIC) was reported at 2.86%, indicating weak capital returns over recent years [3] Business Strategy and Outlook - The company plans to maintain its position as a traditional taurine supplier while also focusing on developing its own brand products in the health and consumer goods market [4] - The management expressed confidence in the taurine market, citing a strong foundation built over 20 years and readiness to capitalize on macroeconomic policies aimed at expanding domestic demand [3][4] - The company emphasizes the importance of its marketing-driven business model and the need to monitor accounts receivable, which currently stands at 182.19% of profits [3]

Group 1 - The core viewpoint of the article highlights that Yong'an Pharmaceutical (002365.SZ) reported a significant decline in both revenue and net profit for the first half of 2025 [1] Group 2 - The company achieved an operating income of 367 million yuan, representing a year-on-year decrease of 13.72% [1] - The net profit attributable to shareholders of the listed company was 12.4957 million yuan, down 76.19% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.2853 million yuan, a decrease of 93.65% year-on-year [1] - The basic earnings per share were 0.0432 yuan [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 367 million yuan, a year-on-year decrease of 13.72% [1] - The net profit attributable to shareholders was 12.4957 million yuan, reflecting a year-on-year decline of 76.19% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.2853 million yuan, down 93.65% year-on-year [1] - Basic earnings per share were reported at 0.0432 yuan [1]

Group 1 - The company Yong'an Pharmaceutical announced the convening of its seventh board meeting on August 27, 2025, to review the semi-annual report and its summary for 2025 [1] - The meeting was held in a hybrid format, combining in-person and remote participation [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

潜江永安药业股份有限公司 2025 年半年度 汇总表第 1页 | | 潜江齐安氢能源发展有 | 控股子公司 | 其他应收款 | | | | | | 借款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 限公司 | | | 5,101.96 | 66.00 | 48.74 | | 5,216.70 | | | | | 湖北凌安科技有限公司 | 控股子公司 | 应收账款 | | | | | | 销售 | 经营性往来 | | | | | | | 557.62 | | 557.62 | | 商品 | | | | 湖北凌安科技有限公司 | 控股子公司 | 其他应收款 | | 800.00 | 0.13 | 800.13 | | 借款 | 非经营性往来 | | | 湖北禾安生物科技有限 | 控股子公司 | 应收账款 | | | | | | 销售 | 经营性往来 | | | 公司 | | | | 2.13 | | 2.13 | | 商品 | | | 其他关联方及其附属企业 | 湖北凌安化学有限公司 | 公司 ...

2025 年半年度财务报告 潜江永安药业股份有限公司 2025 年半年度财务报告全文 潜江永安药业股份有限公司 【2025 年 8 月】 1 潜江永安药业股份有限公司 2025 年半年度财务报告全文 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：潜江永安药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 267,439,688.60 | 320,405,292.96 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 663,569,139.75 | 600,160,393.06 | | 衍生金融资产 | | | | 应收票据 | 14,812,468.14 | 6,712,910.00 | | 应收账款 | 112,529,066.48 | 153,967,383.89 | | 应收款项融资 | 250,000.00 | 1,10 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第八次会议 的会议通知于 2025 年 8 月 15 日以书面、电话、传真、电子邮件等形式送达公司 全体董事，会议于 2025 年 8 月 27 日在公司会议室以现场及通讯相结合的方式召 开，本次会议应出席董事 6 人，实际出席董事 5 人，缺席董事 1 人（董事长陈 勇先生因暂不能正常履职，缺席本次会议），公司部分监事及高管列席了会议。 本次会议由公司董事陈子笛先生主持，会议的召集和召开符合《公司法》及《公 司章程》的规定。会议以书面记名投票方式进行逐项表决，通过了如下决议： 审议通过《关于公司 2025 年半年度报告及其摘要的议案》 表决结果：同意 5 票，反对 0 票，弃权 0 票。 本议案提交董事会前已经公司董事会审计委员会审议通过。 《2025 年半年度报告摘要》刊登于中国证监会指定信息披露媒体《证券时 报》及巨潮资讯网 http://www.cninfo.com.cn。《2025 年半年度报告》刊登于 中国证监会指定信息披露媒体巨潮资讯网 htt ...